Did Gilead just low­er the bar on cru­cial remde­sivir tri­als for Covid-19? Switch­ing end­points, amp­ing up tri­al size stir an­a­lyst­s' fears — and hopes

To say Gilead’s remde­sivir is in the R&D spot­light would be one of the great un­der­state­ments of the year.

The most ad­vanced late-stage an­tivi­ral now in de­vel­op­ment for Covid-19 is seen as a po­ten­tial treat­ment for pop­u­la­tions deeply fright­ened of be­ing killed by the new virus, of­fer­ing a pos­si­ble calm­ing ef­fect for mar­kets where pan­ic runs deep — if the da­ta are pos­i­tive. And that has an­a­lysts read­ing any tea leaves that come their way.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA